Filtros : "Neves, Daniel V." Limpar

Filtros



Refine with date range


  • Source: Fundamental and Clinical Pharmacology. Unidades: FMRP, FCFRP

    Subjects: ANALGÉSICOS, CITOCROMO P-450, ESTEROIDES

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      MORAES, Natália V. de et al. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain. Fundamental and Clinical Pharmacology, v. 30, n. 2, p. 153-161, 2016Tradução . . Disponível em: https://doi.org/10.1111/fcp.12168. Acesso em: 09 jun. 2024.
    • APA

      Moraes, N. V. de, Lauretti, G. R., Coelho, E. B., Godoy, A. L. P. C., Neves, D. V., & Lanchote, V. L. (2016). Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain. Fundamental and Clinical Pharmacology, 30( 2), 153-161. doi:10.1111/fcp.12168
    • NLM

      Moraes NV de, Lauretti GR, Coelho EB, Godoy ALPC, Neves DV, Lanchote VL. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain [Internet]. Fundamental and Clinical Pharmacology. 2016 ; 30( 2): 153-161.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1111/fcp.12168
    • Vancouver

      Moraes NV de, Lauretti GR, Coelho EB, Godoy ALPC, Neves DV, Lanchote VL. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain [Internet]. Fundamental and Clinical Pharmacology. 2016 ; 30( 2): 153-161.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1111/fcp.12168
  • Source: British Journal of Clinical Pharmacology. Unidades: FCFRP, FMRP

    Subjects: NEFROPATIAS, FARMACOCINÉTICA, FENÓTIPOS

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      NEVES, Daniel V. et al. Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers. British Journal of Clinical Pharmacology, v. 82, n. 1, p. 83-91, 2016Tradução . . Disponível em: https://doi.org/10.1111/bcp.12917. Acesso em: 09 jun. 2024.
    • APA

      Neves, D. V., Lanchote, V. L., Moysés Neto, M., Costa, J. A. C. da, Vieira, C. P., & Coelho, E. B. (2016). Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers. British Journal of Clinical Pharmacology, 82( 1), 83-91. doi:10.1111/bcp.12917
    • NLM

      Neves DV, Lanchote VL, Moysés Neto M, Costa JAC da, Vieira CP, Coelho EB. Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers [Internet]. British Journal of Clinical Pharmacology. 2016 ; 82( 1): 83-91.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1111/bcp.12917
    • Vancouver

      Neves DV, Lanchote VL, Moysés Neto M, Costa JAC da, Vieira CP, Coelho EB. Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers [Internet]. British Journal of Clinical Pharmacology. 2016 ; 82( 1): 83-91.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1111/bcp.12917

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2024